Skip to main content

Tango Therapeutics, Inc. (TNGX) Stock Analysis

SellModerate Confidence

Healthcare · Biotechnology

Sell if holding. Engine safety override at $20.83: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 2.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 27%; Below-average business quality; Negative price momentum.

Tango Therapeutics is a clinical-stage precision oncology company developing MTA-cooperative PRMT5 inhibitors for MTAP-deleted cancers. Its lead program vopimetostat showed 27% ORR across cancer types in Phase 1/2 with a pivotal 2L pancreatic cancer trial planned for 2026;... Read more

$20.83+33.6% A.UpsideScore 4.7/10#116 of 157 Biotechnology
QualityF-score2 / 9FCF yield-2.32%
Stop $19.32Target $27.75(analyst − 13%)A.R:R 2.2:1
Analyst target$31.90+53.1%10 analysts
$27.75our TP
$20.83price
$31.90mean
$55

Sell if holding. Engine safety override at $20.83: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 2.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 27%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.7/10, moderate confidence.

Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 77d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.

Val9.0Qual1.7Grw5.0Mom2.1Sent7.6Ins3.6Peer2.1Tech6.2Risk2.84.7OVERALL

Recent Developments — Tango Therapeutics, Inc.

Latest news

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards
No bull case signals
Risks
Concentration risk — Pipeline: vopimetostat
Concentration risk — Supplier: one manufacturer (drug substance)
Quality below floor (1.7 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)-12.8
Mkt Cap$2.9B
EV/EBITDA-22.4
Profit Mgn-188.2%
ROE-38.4%
Rev Growth—
Beta1.22
DividendNone
Rating analysts18

Quality Signals

Piotroski F2/9

Options Flow

P/C0.49bullish
IV121%elevated
Max Pain$15-28.0% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHpipelinevopimetostat
    10-K Item 1: 'vopimetostat (TNG462) for non-CNS cancers...supporting the planned initiation of a 2L pivotal trial in this patient population in 2026.'
  • HIGHSupplierone manufacturer (drug substance)
    10-K Item 1: 'all manufacturing of the drug substance for our product candidates to be used in our clinical trials is conducted by one manufacturer'

Material Events(8-K, last 90d)

  • 2026-04-15Item 5.02MEDIUM
    CFO Daniella Beckman terminated effective April 15, 2026; Matthew Gall appointed successor CFO same day. No reason cited for Beckman's departure. Gall previously CFO at Kalaris Therapeutics and iTeos Therapeutics.
    SEC filing →
  • 2026-05-08Item 5.02LOW
    Separation agreement with former CFO Daniella Beckman executed May 7, 2026: 12 months severance, COBRA reimbursement up to 12 months, accelerated 24-month forward equity vesting, options extended through August 31, 2026.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

4 floor-breakers·1 ceiling hit

Unprofitable operations — net margin -188.2%. Quality floor flags this regardless of sector context.static

Roe
0.0
Roa
0.0
Fcf Quality
0.0
Piotroski F
2.2
Moat
3.2
Current Ratio
5.0
Cash-burning: FCF -120% of revenueNo competitive moatWeak Piotroski F-Score: 2/9Quality concerns

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd
0.0
Volume
0.0
Obv
1.0
Ma Position
4.0
Rsi
5.5
Volume distribution (falling OBV)Above 200-day MA

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Value Rank
1.0
Quality Rank
1.9
Growth Rank
5.0

Volatile — 9.4% daily ATR makes tight stops impractical. Position-size conservatively.static

Days To Cover
0.0
Volatility
0.0
Implied Vol
0.0
Debt Equity
0.0
Short Interest
0.8
Max Pain Risk
3.0
News Risk
5.0
Beta
6.1
Put Call
10.0
High short interest justified: 27%High IV: 121%Above max pain $15Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
GatesMomentum 2.1<4.5A.R:R 2.2 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 77d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive
RSI
47 · Neutral
↓ 20D MA↓ 50D MA↑ 200D MAGOLDEN CROSSSupport $19.34Resistance $27.28

Price Targets

$19
$28
A.Upside+33.2%
A.R:R2.2:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Quality below floor (1.7 < 4.0)
! Momentum score 2.1/10 — below 4.5 minimum

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-08-05 (77d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is TNGX stock a buy right now?

Sell if holding. Engine safety override at $20.83: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 2.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 27%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $19.32. Score 4.7/10, moderate confidence.

What is the TNGX stock price target?

Take-profit target: $27.75 (+33.6% upside). Prior stop was $19.32. Stop-loss: $19.32.

What are the risks of investing in TNGX?

Concentration risk — Pipeline: vopimetostat; Concentration risk — Supplier: one manufacturer (drug substance); Quality below floor (1.7 < 4.0).

Is TNGX overvalued or undervalued?

Tango Therapeutics, Inc. trades at a P/E of N/A (forward -12.8). TrendMatrix value score: 9.0/10. Verdict: Sell.

What do analysts say about TNGX?

18 analysts cover TNGX with a consensus score of 4.3/5. Average price target: $32.

What does Tango Therapeutics, Inc. do?Tango Therapeutics is a clinical-stage precision oncology company developing MTA-cooperative PRMT5 inhibitors for...

Tango Therapeutics is a clinical-stage precision oncology company developing MTA-cooperative PRMT5 inhibitors for MTAP-deleted cancers. Its lead program vopimetostat showed 27% ORR across cancer types in Phase 1/2 with a pivotal 2L pancreatic cancer trial planned for 2026; TNG456 targets GBM. The company has no approved products or product revenue and had an accumulated deficit of $603.2 million as of December 31, 2025.

Related stocks: AUPH (Aurinia Pharmaceuticals Inc) · INCY (Incyte Corporation) · HALO (Halozyme Therapeutics, Inc.) · ADMA (ADMA Biologics Inc) · GLPG (Galapagos NV)